Using ultrasound to assess liver tumor treatment response

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II trial evaluates the effectiveness of contrast-enhanced ultrasound (CEUS) in determining how well patients with liver tumors respond to transarterial chemoembolization (TACE). The study aims to compare CEUS with traditional imaging methods like MRI and CT, which assess treatment response weeks after TACE. By using CEUS during the TACE procedure, the trial seeks to provide earlier and potentially more accurate evaluations of treatment effectiveness. Patients will receive an imaging agent and undergo CEUS at multiple points: before, during, and after the TACE procedure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Scheduled for TACE therapy of a liver tumor
* Be at least 18 years of age
* Be medically stable
* If a female of child-bearing age, must have a negative pregnancy test
* Have signed informed consent to participate in the study

Exclusion Criteria:

* Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable
* Patients with known sensitivities to the components of lumason

Where it's running

• Sidney Kimmel Cancer Center at Thomas Jefferson University
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Study coordinator: John Eisenbrey, PhD
• Email: john.eisenbrey@jefferson.edu
• Phone: 215-503-5188

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Multimodal Survival Predictor for Colorectal Liver Metastases After Surgery

  Researchers are testing a tool that combines MRI-derived tumor features with clinical data to predict survival after surgery for colorectal liver metastases.

  Recruiting Anhui Provincial Hospital · Hefei, Anhui · NCT07830576

• Predicting liver failure after major liver surgery using CT measurements and vascular shape changes

  Doctors are testing whether adding vascular deformation mapping to CT measurements can better predict liver failure after removing a large portion of the liver.

  Recruiting at 3 sites Minia University · Minya, Minya Governorate and 2 other locations · NCT07727759

• Camera-based non-contact vital sign monitoring during surgery

  This project will try a camera-based non-contact system to measure heart rate, blood pressure, and oxygen levels in adults having surgery under general anesthesia.

  Recruiting Taipei Veterans General Hospital, Taiwan · Taipei · NCT07473687

• Blood biomarker changes before and after TACE for hepatocellular carcinoma

  This will see if blood biomarkers change after TACE and whether those changes match early CT/MRI response in adults with hepatocellular carcinoma.

  Recruiting University of Belgrade · Belgrade · NCT07378709

• TheraSphere Y-90 glass microsphere treatment for liver tumors in Japan

  This will test whether TheraSphere Y-90 glass microspheres are safe and helpful for Japanese adults with primary or secondary liver cancer who are not candidates for standard treatments.

  Recruiting at 5 sites Boston Scientific Corporation · Nishinomiya, Hyōgo and 4 other locations · NCT07377487

• Carbon ion radiotherapy plus atezolizumab and bevacizumab for advanced hepatocellular carcinoma

  This trial will try adding carbon ion radiotherapy to standard atezolizumab‑bevacizumab treatment for adults with advanced hepatocellular carcinoma to see if it controls tumors better and improves survival.

  Recruiting Phase 2 Yonsei University · Seoul · NCT07246668

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.